NON RADIOACTIVE METHOD TO MEASURE ORGAN BLOOD FLOW

描述：(改编自申请者摘要)： 建议的研究是验证一种测量局部器官血液的新方法 用中子测定的非放射性、稳定标记微球的流动 激活(NA)分析。这项提议是基于这样一个假设： 引入生物基质的稳定标记的研究产品可以 使用NA准确、快速地进行检测。这项技术将提供一种 减少低水平放射性物质生产的经济有效的方法 生物医学研究产生的废物。我们的长远目标是发展 基于NA技术的额外研究产品，可用于 当前非放射性方法是劳动密集型和较少的应用 有效。拟议项目的第一阶段是内部阿尔法测试，它将 直接比较稳定标记的微球和联合注射的放射性标记的 微球在兔冠状动脉闭塞和再灌流模型中的应用。 统计分析将用于评估两种方法之间的一致性， 从而支持了工作假说，论证了可行性。阶段 我还将提供自动激活的重要设计参数和 将在第二阶段建设计数系统。这个自动化系统将 能够对商业所需的大量样品进行分析 手术。 建议的商业应用：不可用

DESCRIPTION: (Adapted from applicant's abstract): The specific aim of the proposed study is to validate a new method of measuring regional organ blood flow using non-radioactive, stable-labeled microspheres assayed by neutron activation (NA) analysis. The proposal is based on the hypothesis that stable-labeled research products introduced into a biological matrix can be accurately and rapidly assayed using NA. This technology will provide a cost-effective method for reducing the production of low-level radioactive waste generated from biomedical research. The long-term goal is to develop additional research products based on the NA technology, which could be used in applications where current non-radioactive methods are labor-intensive and less effective. Phase I of the proposed project is an in-house alpha test which will directly compare stable-labeled microspheres to a co-injection of radiolabeled microspheres in an in vivo rabbit model of coronary occlusion and reperfusion. Statistical analysis will be used to assess agreement between the two methods, thereby supporting the working hypothesis and demonstrating feasibility. Phase I will also provide important design parameters for an automated activation and counting system to be constructed during Phase II. This automated system will be able to assay the large numbers of samples necessary for commercial operation. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE